Literature DB >> 26113317

Current incidence of clinical kernicterus in preterm infants in Japan.

Ichiro Morioka1,2, Hajime Nakamura1,2, Tsubasa Koda1,2, Tomoyuki Yokota1,2, Hitoshi Okada3,2, Yoshinori Katayama4,2, Tetsuya Kunikata5,2, Masatoshi Kondo6,2, Makoto Nakamura7,2, Shigeharu Hosono8,2, Saneyuki Yasuda3,2, Naoki Yokoyama9,2, Hiroshi Wada10,2, Susumu Itoh3,2, Masahisa Funato10,2, Yoshitada Yamauchi11,2, Yong Kye Lee12,2, Masahiko Yonetani13,2.   

Abstract

Clinical kernicterus in preterm infants has recently been reported in Japan, diagnosed on the basis of clinical findings during the neonatal and infancy periods. We investigated the incidence of clinical kernicterus in preterm infants <30 weeks gestational age (GA) based on a nationwide survey conducted in 233 certified educational facilities for neonatologists. The numbers of infants admitted and infants who died within 14 days after birth during 2011, and the number of infants who subsequently developed clinical kernicterus, were recorded. A total of 2720 infants were analyzed, representing 59% (2720/4623) of all preterm live births <30 weeks GA in Japan in 2011. Of these, 159 (5.8%) died within 14 days after birth, similar to the national rate. Five infants developed clinical kernicterus in infancy (5/2720, 0.18%). The current incidence of clinical kernicterus in Japan is therefore estimated at 1.8 per 1000 live births <30 weeks GA.
© 2015 Japan Pediatric Society.

Entities:  

Keywords:  Japan; incidence; kernicterus; preterm infant

Mesh:

Year:  2015        PMID: 26113317     DOI: 10.1111/ped.12651

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  7 in total

Review 1.  Developmental, Genetic, Dietary, and Xenobiotic Influences on Neonatal Hyperbilirubinemia.

Authors:  Mei-Fei Yueh; Shujuan Chen; Nghia Nguyen; Robert H Tukey
Journal:  Mol Pharmacol       Date:  2017-03-10       Impact factor: 4.436

2.  Fluorescent protein-based detection of unconjugated bilirubin in newborn serum.

Authors:  Sota Iwatani; Hajime Nakamura; Daisuke Kurokawa; Keiji Yamana; Kosuke Nishida; Sachiyo Fukushima; Tsubasa Koda; Noriyuki Nishimura; Hisahide Nishio; Kazumoto Iijima; Atsushi Miyawaki; Ichiro Morioka
Journal:  Sci Rep       Date:  2016-06-21       Impact factor: 4.379

Review 3.  Bilirubin Induced Encephalopathy.

Authors:  Parvaneh Karimzadeh; Minoo Fallahi; Mohammad Kazemian; Naeeme Taslimi Taleghani; Shamsollah Nouripour; Mitra Radfar
Journal:  Iran J Child Neurol       Date:  2020

4.  A Novel Method for Measuring Serum Unbound Bilirubin Levels Using Glucose Oxidase-Peroxidase and Bilirubin-Inducible Fluorescent Protein (UnaG): No Influence of Direct Bilirubin.

Authors:  Sota Iwatani; Keiji Yamana; Hajime Nakamura; Kosuke Nishida; Takeshi Morisawa; Masami Mizobuchi; Kayo Osawa; Kazumoto Iijima; Ichiro Morioka
Journal:  Int J Mol Sci       Date:  2020-09-16       Impact factor: 5.923

5.  Albumin administration prevents neurological damage and death in a mouse model of severe neonatal hyperbilirubinemia.

Authors:  Simone Vodret; Giulia Bortolussi; Andrea B Schreuder; Jana Jašprová; Libor Vitek; Henkjan J Verkade; Andrés F Muro
Journal:  Sci Rep       Date:  2015-11-06       Impact factor: 4.379

6.  Quantitative proteomic characterization of microvesicles/exosomes from the cerebrospinal fluid of patients with acute bilirubin encephalopathy.

Authors:  Ning Tan; Shuiwang Hu; Zhen Hu; Zhouli Wu; Bin Wang
Journal:  Mol Med Rep       Date:  2020-05-28       Impact factor: 2.952

7.  Long-Term Effects of Biliverdin Reductase a Deficiency in Ugt1-/- Mice: Impact on Redox Status and Metabolism.

Authors:  Giulia Bortolussi; Xiaoxia Shi; Lysbeth Ten Bloemendaal; Bhaswati Banerjee; Dirk R De Waart; Gabriele Baj; Weiyu Chen; Ronald P Oude Elferink; Ulrich Beuers; Coen C Paulusma; Roland Stocker; Andrés F Muro; Piter J Bosma
Journal:  Antioxidants (Basel)       Date:  2021-12-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.